China Fund News | STAR Market Pharmaceutical Companies Intensively Disclose R&D Progress: Yahong Meditech' Globally First-in-Class Product Approved for Marketing

China Fund News, March 4 — On the evening of March 3, 6 biopharmaceutical companies listed on the STAR Market, including Yahong Meditech, Bio-Thera Solutions, and Hinova Pharmaceuticals, collectively disclosed progress in drug registration and R&D. Yahong Meditech announced that it had received a Drug Registration Certificate issued and approved by the National Medical Products Administration (NMPA), granting marketing approval for APL-1702 (Cevira) for the treatment of patients aged 18 years and above with histologically confirmed cervical intraepithelial neoplasia grade 2 (CIN2). The product has become the world's first non-surgical, non-invasive therapeutic approved for marketing specifically for this patient population. Bio-Thera Solutions announced that Usymro® (ustekinumab injection) has received marketing authorization from the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom. The product is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, and other indications. To date, the product has been approved for marketing by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the UK MHRA. Its commercialization and licensing partnerships currently cover 71 countries and regions worldwide. The intensive wave of R&D progress highlights the robust innovation capabilities of biopharmaceutical companies listed on the STAR Market.